G-CSF alone mobilizes sufficient peripheral blood CD34 sup + cells for positive selection in newly diagnosed patients with myeloma and lymphoma

Mahe, B.
Milpied, N.
Hermouet, S.
Robillard, N.
Moreau, P.
Letortorec, S.
Rapp, M.J.
Bataille, R.
Harousseau, J. L.

Laboratoire d'Hematologie, Institut de Biologie, Hotel Dieu, Nantes, and Service d'Hematologie, CHU Hotel Dieu, Nantes, France (N. Milpied, P. Moreau, S. Letortorec, M. J. Rapp, J. L. Harousseau).
Received 26 September 1995; accepted for publication 9 October 1995
Correspondence: Dr B. Mahe, Laboratoire d'Hematologie, Institut de Biologie, 9 quai Moncousu, B.P. 1005, 44035 Nantes Cedex 01, France.

British Journal of Haematology 92(2):p 263-268, February 1996.

Summary

We have evaluated CD34 sup + cell positive selection from granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells (PBPC) in 26 patients with either multiple myeloma (MM, n=18) or follicular non-Hodgkin's lymphoma (NHL, n=8). 26 PBPC were collected with two leukaphereses: 16 contained sufficient numbers of CD34 sup + cells and were selected. The absolute number of CD34 sup + cells in the leukapheresis products was found to be significantly related to the duration of underlying disease and exposure to prior treatment. CD34 sup + cell positive selection allowed recovery of a median of 35 percent of CD34 sup + cells, the selected fraction containing a median number of 1.43 X 10⁶ /kg CD34 sup + cells/kg (range 0.48-41.5). 10 patients were transplanted and received a median dose of 1.51 X 10⁶ CD34 sup + cells (range 0.48-4.2). The median time to granulocyte (greater than 0.5 X 10⁹ /l) and platelet (greater than 20 X 10⁹ /l) engraftment was 12 and 13 d respectively (ranges 10-13 and 0-95). Lymphoma cells were found by a sensitive polymerase chain reaction technique in four out of five CD34 sup + cell fractions tested.